Replimune Group Quarterly Cash Flow Statement
NASDAQ: REPLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
19.07-0.16 (-0.83%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Replimune Group free cash flow
In the quarter ended Sep 30, 2026, Replimune Group generated -$47.7 million of operating cash flow and spent $77,000 on capital expenditures. That left free cash flow of -$47.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Replimune Group cash flow statement (quarterly)
| Quarter (USD) | Q2 20272026-09-30 | Q1 20272026-06-30 | Q4 20262026-03-31 | Q3 20262025-12-31 | Q2 20262025-09-30 | Q1 20262025-06-30 | Q4 20252025-03-31 | Q3 20252024-12-31 | Q2 20252024-09-30 | Q1 20252024-06-30 | Q4 20242024-03-31 | Q3 20242023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -57.12M | -69.77M | -73.22M | -70.93M | -83.10M | -86.69M | -74.13M | -66.34M | -53.05M | -53.77M | -55.08M | -51.12M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 800.00K | 937.00K | 769.00K | 800.00K | 800.00K | 873.00K | 848.00K | 1.00M | 900.00K | 736.00K | 705.00K | 700.00K |
| Stock-Based Compensation | 10.54M | 7.67M | 8.13M | 7.05M | 8.34M | 8.76M | 8.28M | 8.64M | 8.65M | 9.47M | 7.92M | 8.24M |
| Change in Working Capital | 788.00K | 795.00K | 594.00K | -694.00K | -9.07M | 4.00M | 4.89M | -643.00K | 5.24M | 202.00K | -856.00K | -444.00K |
| Operating Cash Flow | -47.70M | -75.73M | -56.16M | -65.95M | -81.21M | -77.02M | -53.73M | -50.71M | -38.64M | -49.17M | -46.17M | -47.12M |
| Capital Expenditures | -77.00K | -6.00K | -5.00K | -135.00K | -1.34M | -2.74M | -1.13M | -1.80M | -2.08M | -1.67M | -1.74M | -1.72M |
| Investing Cash Flow | 9.76M | 49.99M | 86.51M | 75.12M | 84.17M | 65.05M | -7.70M | -46.32M | 458.00K | 29.77M | 23.20M | 53.96M |
| Debt Issued | — | — | — | — | — | — | 0 | — | — | — | 0 | — |
| Financing Cash Flow | 160.55M | 800.00K | 55.68M | 10.45M | 324.00K | -158.00K | -132.00K | 155.93M | -39.00K | 96.64M | -130.00K | 14.87M |
| Net Change in Cash | 122.47M | -23.66M | 86.07M | 20.65M | 4.92M | -13.74M | -61.12M | 58.75M | -38.16M | 77.20M | -23.15M | 21.68M |
| Free Cash Flow | -47.78M | -75.73M | -56.17M | -66.09M | -82.56M | -79.76M | -54.87M | -52.51M | -40.72M | -50.84M | -47.91M | -48.84M |
This table shows 12 quarterly periods of Replimune Group's cash flow statement, from Q2 2027 back to Q3 2024, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow REPL's reporting calendar. What is a cash flow statement?